Alice Chen on Muck Rack

Alice Chen

San Francisco
As seen in: Color Research & Application, Nature, USA Today, Wiley Online Library, South China Morning Post, The Epoch Times, Benefits Canada, Lake County Record-Bee, Greenville Journal, Montecristo Magazine and
social  | formerly @hellosunshine, @britandco, @yahoo, @hercampus, @luckymagazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alice

Contact Alice, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

|
By Priscilla Merriam, James Morrow Verified, Emanuele Mazzola, Nicole L. Solimini, Prafulla C. Gokhale, Ping Chi, Alice Chen, Mark Agulnik, Melissa Burgess, Scott M Schuetze, Neeta Somaiah, Brian Van Tine, Seth Pollack, Gabriel Tinoco, Jonathan C. Trent, Breelyn Wilky, Nicola Bothwick, Benjamin K. Eschle, Vivian Nguyen, Jan H. Beumer, Noushin Rastkari, Shahanawaz Jiwani, Peter Wu, Lorraine C. Pelosof, Matthew Hemming, Geoffrey I. Shapiro, George D. Demetri, Bradley E. Bernstein, Suzanne George
| Nature Verified
Abstract While most gastrointestinal stromal tumors are driven by oncogenic mutations in KIT or PDGFRA, 10–15% exhibit functional loss of the succinate dehydrogenase (SDH) complex and genome-wide DNA hypermethylation. Excess methylation in SDH-deficient gastrointestinal stromal tumors disrupts genomic insulators, inducing aberrant expression of oncogenic ligands FGF3, FGF4, and activating an autocrine signaling loop mediated through FGFR1.
Open in Who Shared Issue with article?

Measuring the multidimensional aspects of tolerability

|
By Sandra Mitchell, Rachel D Altshuler, Brennan Parmelee Streck, Alice Chen
| Wiley Online Library Verified
EVOLVING PERSPECTIVES ON CANCER TREATMENT TOLERABILITY Safety and tolerability are fundamental to drawing conclusions about the effectiveness of cancer therapies, including comparative effectiveness, and complement clinical trial end points such as progression-free survival, overall survival, and clinical benefit.1 All cancer-directed therapies have the potential to cause toxicities that can result in early treatment discontinuation, dose reductions, or patient nonadherence to therapy and, as...
Open in Who Shared Issue with article?

National Cancer Institute Cancer Treatment Tolerability Consortium: Current status and future directions

|
By Rachel D Altshuler, Sandra Mitchell, Alice Chen, Brennan Parmelee Streck
| Wiley Online Library Verified
BACKGROUND Understanding cancer treatment tolerability is important in gauging the risks and benefits of a treatment regimen, optimizing the dosing and scheduling of that regimen, and providing information for clinicians to communicate to patients the possible adverse events (AEs) and ways in which those AEs can be mitigated and managed.
Open in Who Shared Issue with article?
See all 38 licensed articles (41 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified